Is Serum Uric Acid Level an Independent Predictor of Heart Failure Among Patients With Coronary Artery Disease?

被引:39
作者
Eisen, Alon [1 ]
Benderly, Michal [2 ,3 ]
Goldbourt, Uri [3 ]
Haim, Moti [1 ]
机构
[1] Rabin Med Ctr, Dept Cardiol, IL-49100 Petah Tiqwa, Israel
[2] Chaim Sheba Med Ctr, Gertner Inst Epidemiol & Hlth Res Policy, IL-52621 Tel Hashomer, Israel
[3] Tel Aviv Univ, Sackler Fac Med, Dept Epidemiol & Prevent Med, Sch Publ Hlth, IL-69978 Tel Aviv, Israel
关键词
ATHEROSCLEROSIS RISK; COMPETING RISKS; LONG-TERM; MORTALITY;
D O I
10.1002/clc.22083
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Uric acid (UA) is elevated in patients with the metabolic syndrome, and there is a possible association with coronary events. Its association with future risk of heart failure (HF) is not clear. Our objective was to evaluate the association between levels of UA and risk of HF in patients with stable coronary artery disease (CAD). Hypothesis: Serum UA is associated with HF in CAD patients. Methods: A retrospective cohort analysis among 2939 participants of the bezafibrate infarction prevention study, assessing long-term risk of HF incidence over an 8-year of follow-up in relation to baseline UA. Results: Among patients with high levels of UA, there was a larger proportion of men, systolic hypertension, diabetes mellitus, metabolic syndrome, elevated total cholesterol, chronic renal failure, and previous coronary revascularization procedures. The rate of myocardial infarction during the follow-up was 10.9%, 10.3%, and 11.6% in the 1st, 2nd and 3rd tertiles of UA, respectively (P = 0.68). Age-adjusted hazard ratios for HF were 1.16 (95% confidence interval [CI]: 0.941.45) and 1.28 (95% CI: 1.041.59) in the 2nd and 3rd tertiles, respectively, as compared to the 1st tertile. After adjusting for multiple confounders and myocardial infarction, the hazard ratio for developing HF was 1.18 (95% CI: 0.951.47) and 1.25 (95% CI: 1.001.56) in the 2nd and 3rd tertiles of UA levels, respectively. Conclusions: UA levels are associated with future risk of HF in patients with stable CAD, but this association is attenuated after adjusting for traditional CAD risk factors. The authors have no funding, financial relationships, or conflicts of interest to disclose.
引用
收藏
页码:110 / 116
页数:7
相关论文
共 26 条
[1]   Serum uric acid and cardiovascular disease: Recent developments, and where do they leave us? [J].
Baker, JF ;
Krishnan, E ;
Chen, L ;
Schumacher, HR .
AMERICAN JOURNAL OF MEDICINE, 2005, 118 (08) :816-826
[2]   Uric acid: A marker of increased cardiovascular risk [J].
Gagliardi, Ana C. M. ;
Miname, Marcio H. ;
Santos, Raul D. .
ATHEROSCLEROSIS, 2009, 202 (01) :11-17
[3]   Evaluation of Risk Factors for Cataract Types in a Competing Risks Framework [J].
Glynn, Robert J. ;
Rosner, Bernard ;
Christen, William G. .
OPHTHALMIC EPIDEMIOLOGY, 2009, 16 (02) :98-106
[4]   RATIONALE AND DESIGN OF A SECONDARY PREVENTION TRIAL OF INCREASING SERUM HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL AND REDUCING TRIGLYCERIDES IN PATIENTS WITH CLINICALLY MANIFEST ATHEROSCLEROTIC HEART-DISEASE (THE BEZAFIBRATE INFARCTION PREVENTION TRIAL) [J].
GOLDBOURT, U ;
BEHAR, S ;
REICHERREISS, H ;
AGMON, J ;
KAPLINSKY, E ;
GRAFF, E ;
KISHON, Y ;
CASPI, A ;
WEISBORT, J ;
MANDELZWEIG, L ;
ABINADER, E ;
AHARON, L ;
BRAUN, S ;
DAVID, D ;
FLICH, M ;
FRIEDMAN, Y ;
KRISTAL, N ;
LEIL, N ;
MARKIEWICZ, W ;
MARMOR, A ;
PALANT, A ;
PELLED, B ;
RABINOWITZ, B ;
REISIN, L ;
ROGUIN, N ;
ROSENFELD, T ;
SCHLESINGER, Z ;
SCLAROVSKY, S ;
SHERF, L ;
TZIVONI, D ;
ZAHAVI, I ;
ZION, M ;
BRUNNER, D ;
FRIDENSOHN, A ;
JAFARI, J ;
OSTFELD, B ;
ROCHFLEISH, S ;
SCHNEIDER, H ;
KHALID, S ;
NARINSKY, R ;
ROTZAK, R ;
VITRAI, J ;
PELLED, B ;
PARDU, J ;
LANIADO, S ;
ESHCHAR, Y ;
ARDITI, A ;
BOTWIN, S ;
ROGUIN, N ;
YAHALOM, M .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (11) :909-915
[5]  
Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO
[6]  
2-F
[7]   A CLASS OF K-SAMPLE TESTS FOR COMPARING THE CUMULATIVE INCIDENCE OF A COMPETING RISK [J].
GRAY, RJ .
ANNALS OF STATISTICS, 1988, 16 (03) :1141-1154
[8]   Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [J].
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, R ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Cleeman, JI ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ ;
Keller, SA ;
Jehle, AJ .
CIRCULATION, 2002, 106 (25) :3143-3421
[9]   Hyperuricemia predicts adverse outcomes in patients with heart failure [J].
Hamaguchi, Sanae ;
Furumoto, Tomoo ;
Tsuchihashi-Makaya, Miyuki ;
Goto, Kazutomo ;
Goto, Daisuke ;
Yokota, Takashi ;
Kinugawa, Shintaro ;
Yokoshiki, Hisashi ;
Takeshita, Akira ;
Tsutsui, Hiroyuki .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 151 (02) :143-147
[10]  
Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO